NKG2D CAR-T cell therapy (Uwell Biopharma)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameNKG2D CAR-T cell therapy (Uwell Biopharma)

Drug Alias NameUWN2D

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionNKG2-D type II integral membrane protein antagonists

TargetsNKG2-D type II integral membrane protein

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusClinical

Highest Status in ChinaN/A

Originator CompaniesUwell Biopharma

China Registration ClassN/A

Develop Information

Active CompaniesUwell Biopharma

Inactive CompaniesN/A

Active IndicationsNeoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A